Disclosures herein are directed to chemically defined animal-derived component free supplements designed for individual cell types that supports the ex vivo growth of cells as well or better than serum, in chemically defined conditions.

Disclosures herein are directed to chemically defined animal-derived component free supplements designed for individual cell types that supports the ex vivo growth of cells as well or better than serum, in chemically defined conditions.

Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.

A composite material film for expanding circulating tumor cells ex vivo and a preparation method thereof, a kit and a method for expanding circulating tumor cells ex vivo, a method for detecting an effect of a drug, and a cryopreservation solution are provided. The preparation method includes: mixing one or more kinds of particles and a solvent to form a mixed liquid, in which the particles are selected from the group consisting of metal particles, metal oxide particles, silicon oxide particles and combinations thereof; placing the mixed liquid on a substrate to form a particle layer; adding a medium material to the particle layer, in which the medium material is selected from the group consisting of styrene and its derivatives, polyester monomers, silicon oxide compounds and combinations thereof; and polymerizing the medium material to form a medium layer to fix the particle layer on the substrate.

The present invention relates to a chemically defined medium for eukaryotic cell culture, comprising water, at least one carbon source, one or more vitamins, one or more salts, one or more growth factors, one or more fatty acids, one or more buffer components, selenium and one or more further trace elements and its use in the culture of cancer stem cells, in particular tumorsphere culture of cancer stem cells.

The present invention relates to a method of transporting a stem cell population, the method comprising transporting the stem cell population contacted with a liquid carrier. In addition, the present invention concerns a method of treating a subject having a disease, the method comprising topically administering a defined mesenchymal stem cell population to the subject, wherein the mesenchymal stem cell population is administered within about 96 hours from the time point the mesenchymal stem cell population has been harvested. Also concerned is a unit dosage comprising about 20 million cells, of about 15 million cells, of about 10 million cells, of about 5 million cells, of about 4 million cells, of about 3 million cells, of about 2 million cells, of about 1 million cells, of about 0.5 million cells, of about 0.25 million cells or of less than 0.25 million cells of a defined mesenchymal stem cell population.

The present invention relates to a method for in-vitro production of mammalian neurons expressing the 6 isoforms of the Tau protein (2N4R, 1N4R, 0N4R, 2N3R, 1N3R, 0N3R), comprising a step of neuronal differentiation, in which cellular microcompartments are cultivated for a period of 5 weeks to 100 weeks, each one comprising a hollow hydro gel capsule surrounding post-mitotic neuronal cells and an extracellular matrix, the neuronal differentiation step being carried out in a bioreactor, the cellular microcompartments being kept in suspension in an enclosure of the bioreactor containing a neuronal differentiation medium.

A method for producing astaxanthin, comprising: (a) acquiring vegetative cells of astaxanthin-producing Haematococcus pluvialis; (b) heterotrophically culturing the vegetative cells of astaxanthin-producing Haematococcus pluvialis in a nutrient-poor culture medium containing an organic carbon source and under a no-light condition, to obtain spore cells; and (c) harvesting the spore cells and/or astaxanthin, and optionally purifying the astaxanthin. Also provided is a culture medium used in the described method.

Methods for developing disease-related nanobodies and related products and kits are provided. The disease-specific proteins are extracellular matrix (ECM) proteins, domains or epitopes that are associated with various aspects of disease and are not present, or are present in very low quantities, in non-diseased individuals. Highly effective nanobodies capable of specifically binding to these ECM protein epitopes useful in in vivo imaging assays, the detection, diagnosis and treatment of diseases as well as monitoring therapeutic progress in a patient with a disease are provided herein.

Provided herein are blastoids and methods for producing the same that are obtained from an extended pluripotent stem (EPS) cell. The herein-disclosed methods provide a unique and highly malleable in vitro system for studying early preimplantation development. Also provided are EPS-blastoids derived from a somatic cell.